Prospective assessment in newborns of diabetes autoimmunity (PANDA): Maternal understanding of infant diabetes risk

Genetics in Medicine

Volumn 5, Issue 2, 2003, Pages 77-83

  Carmichael, Stacy K ^b   Johnson, Suzanne Bennett ^a   Baughcum, Amy ^b   North, Kerri ^c   Hopkins, Diane ^c   Dukes, Margaret G ^d   She, Jin Xiong ^c   Schatz, Desmond A ^d  

^a FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Genetic screening; Newborn; Parental understanding; Risk communication; Type 1 diabetes

Indexed keywords

ACADEMIC ACHIEVEMENT; ACCURACY; ANXIETY; ARTICLE; AUTOIMMUNITY; ETHNIC GROUP; FAMILY HISTORY; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENETIC RISK; GENETIC SCREENING; HEALTH PROGRAM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERVIEW; MAJOR CLINICAL STUDY; MATERNAL CARE; NEWBORN; NEWBORN DISEASE; PREDICTION; PROSPECTIVE STUDY; RISK ASSESSMENT; STANDARD;

COMPREHENSION; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC SCREENING; HUMANS; INFANT, NEWBORN; LOGISTIC MODELS; PATIENT EDUCATION; RISK ASSESSMENT;

PANDA;

EID: 0043062874     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000055196.67008.1B     Document Type: Article

References (59)

1. Bottoroff JL, Ratner PA, Johnson JL, Lovato CY, Joab SA. Communication cancer risk information: The challenges of uncertainty. Patient Educ Couns 1998;33:67-81.
2. Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: A systematic review. Eur J Hum Genet 2000;8:731-738.
3. Lerman C, Croyle RT, Tercyak KP, Hamann H. Genetic testing: Psychological aspects and implications. J Couns Clin Psychol 2002;3:784-797.
4. Browner CH, Preloran M, Press NA. The effects of ethnicity, education and an informational video on pregnant women's knowledge and decisions about a prenatal diagnostic screening test. Patient Educ Couns 1996;27:125-146.
5. Tluczek A, Mischler EH, Bowers B, Peterson N, Morris ME, Farrell PM et al. Psychological impact of false-positive results when screening for cystic fibrosis. Pediatr Pulmonol Suppl 1991;7:29-31.
6. Kong A, Barnett GO, Mosteller F, Youtz C. How medical professionals evaluate expressions of probability. N Engl J Med 1986;315:740-744.
7. Shaw NJ, Dear PRF. How do parents of babies interpret qualitative expressions of probability? Arch Dis Child 1990;65:520-523.
8. Donovan KA, Tucker DC. Knowledge about genetic risk for breast cancer and perceptions of genetic testing in a sociodemographically diverse sample. J Behav Med 2000;23:15-16.
9. Duster T, Beeson D. Pathways and Barriers to Genetic Testing and Screening: Molecular Genetics Meets the "High-Risk Family." Berkeley, CA: Institute for the Study of Social Change, University of California, 1997.
10. Hughes C, Gomez-Caminero A, Benkendorf J, Kerner J, Isaacs C, Barter J et al. Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ Couns 1997;32:51-62.
11. Flynn J, Slovic P, Mertz CK. Gender, race and perception of environmental health risks. Risk Anal 1994;14:1101-1108.
12. Farmer AJ, Levy JC, Turner RC. Perceptions of risk of diabetes and anxiety following screening for type II diabetes [abstract]. Diabetes 1999;48(suppl 1):A321.
13. Lerman C, Kash K, Stefanek M. Younger women at increased risk for breast cancer: Perceived risk, psychological well-being, and surveillance behavior. J Natl Cancer Inst Monogr 1994(16):171-176.
14. Chase GA, Faden RR, Holtzman NA, Chwalow AJ, Leonad CO, Lopes C et al. Assessment of risk by pregnant women: Implications for genetic counseling and education. Soc Biol 1983;33:57-64.
15. Kessler S. Psychological aspects of genetic counseling, VI: A critical review of the literature dealing with education and reproduction. Am J Med Genet 1989;34:340-353.
16. Sorensen JR, Swazey JP, Scotch NA, Kavanagh CM, Matthews DB. Reproductive pasts, reproductive futures: Genetic counseling and its effectiveness. Birth Defects Orig Artic Ser 1981;17:1-192
17. Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kaariainen H. Comprehension of cancer risk one and 12 months after predictive genetic testing for hereditary non-polyposis colorectal cancer [letters]. J Med Genet 2001;38:787-792.
18. Ormond KE, Pergament E, Fine BA. Pre-screening education in multiple marker screening programs: The effect on patient anxiety and knowledge. J Genet Couns 1996;5:69-80.
19. Weston J, Hannah M, Downes J. Evaluating the benefits of a patient information video during the informed consent process. Patient Educ Couns 1997;30:239-245.
20. Codori A, Brandt J. Psychological costs and benefits of predictive testing for Huntington's disease. Am J Med Genet 1994;54:174-181.
21. National Science Foundation. Science, and engineering indicators, 2001. Available at http://www.nsf.gov/sbe/srs/seind00/access/c4/c4s6.htm#c4s615b. Accessed on December 11, 2002.
22. Bernhardt BA, Geller G, Strauss M, Helzlsouer KJ, Stefanek M, Wilcox PM et al. Towards a model of informed consent process for BRCA1 testing: A qualitative assessment of women's attitudes. J Genet Couns 1997;6:207-222.
23. Henneman L, Poppelaars FA, Ten Kate LP. Evaluation of cystic fibrosis carrier screening programs according to genetic screening criteria. Genet Med 2002;4:241-249.
24. Lerman C, Shwartz MD, Miller SM, Daly M, Sands C, Rimer BK. A randomized trial of breast cancer risk counseling: Interaction effects of counseling, educational level, and coping style. Health Psychol 1996;15:75-83.
25. Markel H. The stigma of disease: Implications of genetic screening. Am J Med 1992;93:209-215.
26. Baskin LB, Wians FJ Jr., Elder F. Preconception and prenatal screening for cystic fibrosis. MLO Med Lab Obs 2002;34:8-12.
27. Axworthy D, Brock DJH, Bobrow M, Marteau T. Psychologic impact of population-based carrier testing for cystic fibrosis: 3-year-follow up. Lancet 1996;347:1443-1446.
28. Mayoralas MF, Arce S, Castello CJ. Diagnostico precoz de la distrofia musclar de Duchenne mediante screening neonatial no selectivol [Early diagnosis of Duchenne muscular dystrophy by means of nonselective neonatal screening]. Rev Neurol 2002;35:595-596.
29. Bradley DM, Parsons EP, Clarke A. Experience with screening newborns for Duchenne muscular dystrophy in Wales. BMJ 1993;306:357-360.
30. Marteau TM, Michie S. A positive screening test for an untreatable condition provides psychological relief from uncertainty [letter]. Br J Med 1995;311:58-59.
31. Wells SA Jr., Skinner MA. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998;1061:29-34.
32. Bekker H, Denniss G, Modell M, Bobrow M, Marteau T. The impact of population-based screening for carriers of cystic fibrosis. J Med Genet 1994;31:364-368.
33. Watson E, Mayall E, Lamb J, Chapple J, Williamson B. Psychological and social consequence of community carrier screening programmes for cystic fibrosis. Lancet 1992;340:217-220.
34. Fanos JH, Johnson JP. Perception of carrier status by cystic fibrosis siblings. Am J Hum Genet 1995;57:431-438.
35. Edwards S, Lilford RJ, Thornton J, Hewison J. Informed consent for clinical trials: In search of the "best" method. Soc Sci Med 1998;47:1825-1840.
36. Sliva MC, Sorrell JM. Enhancing comprehension of information for informed consent: A review of empirical research. IRB 1998;10:1-5.
37. Tymchuk AJ. Informing for consent: Concepts and methods. Can Psychol 1998;38:55-75.
38. Verheggen FW, Jonkers R, Kok G. Patients' perceptions of informed consent and the quality of information disclosure in clinical trials. Patient Educ Couns 1996;29:147-153.
39. Dahlquist G, Blom L, Holmgren G, Hogglof B, Larsson Y, Sterky G. The epidemiology of diabetes in Swedish children 0-14 years: A six year prospective study. Diabetologia 1985;28:802-808.
40. LaPorte RM, Matsushima M, Chang Y. Prevalence and incidence of insulin-dependent diabetes. In: Harris MI, editor. Diabetes in America, 2nd ed. Bethesda, MD: National Diabetes Data Group, NIH, 1995:37-44.
41. Akerblom HK, Savilahti E, Saukkonen TT, Paganus A, Virtanen SM, Teramo K et al. The case for elimination of cow's milk in early infancy in the prevention of type I diabetes: The Finnish experience. Diabetes Metab Res Rev 1993;9:269-278.
42. Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M et al. Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 1996;39:807-812.
43. Schatz D, Muir A, Fuller K, Atkinson M, Crockett S, Hsiang H et al. Risk and characteristics of type I diabetes [abstract]. Diabetes 2000;49(suppl 1):A67.
44. Wagner A, Tibben A, Bruining GJ, Aanstoot HJ, Tiems I, Blondeau MJ et al. Preliminary experience with predictive testing for insulin-dependent diabetes mellitus. Lancet 1995;246:380-381.
45. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Antibody appearance and risk for development of childhood diabetes in offspring of parents with type I diabetes: The 2-year analysis of the German BABYDIAB study. Diabetes 1999;48:460-468.
46. Knip M. Prediction and prevention of type 1 diabetes. Acta Paediatr Suppl 1998;425:54-62.
47. Tercyak KP, Streisand R, Peshkin B, Lerman C. Psychosocial impact of predictive testing for illness on children and families: Challenges for a new millennium. J Clin Psychol Med Settings 2000;7:55-68.
48. Johnson SB. Screening programs to identify children at risk for diabetes mellitus: Psychological impact on children and parents. J Pediatr Endocrinol Metab 2001;14:653-659.
49. Johnson SB, Riley WJ, Hansen CA, Nurick MA. Psychological impact of islet cell-antibody screening. Diabetes Care 1990;13:93-97.
50. Johnson SB, Tercyak K. Psychological impact of islet cell antibody screening for IDDM on children, adults, and their family members. Diabetes Care 1995;8:1370-1372.
51. Johnson SB, Carmichael SLK. At-risk for diabetes: Coping with the news. J Clin Psychol Med Settings 2000;7:69-78.
52. Carmichael SLK, Johnson SB, Fuller KG, Taylor KR, She JX, Schatz DA. Newborn genetic screening for type I diabetes: Psychological impact and factors predicting continued participation [abstract]. Diabetes 1999;48(suppl 1):A322.
53. Schatz D, Muir A, Fuller K, Atkinson M, Crockett S, Huang H et al. Prospective assessment in newborns for diabetes autoimmunity (PANDA): A newborn screening program in the general population of Florida [abstract]. Diabetes 2000;49(suppl 1):A67.
54. Schatz D, Krisher J, She X. To screen or not to screen for pre-type I diabetes? Horm Res 2002;57(suppl 1):12-17.
55. Spielberger CD, Gorsuch RL, Lushene R. Test Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, 1970.
56. Evans DGR, Blair V, Greenhalgh R, Hopwood P, Howell A. The impact of genetic counseling on risk perception in women with a family history of breast cancer. Br J Cancer 1994;70:934-938.
57. Lerman C, Schwartz MD, Miller SM, Daly M, Sands C, Rimer BK. A randomized trial of breast cancer risk counseling: Interacting effects of counseling, educational level, and coping style. Health Psychol 1996;15:75-83.
58. Lerman C. Translational behavioral research in cancer genetics. Prev Med 1997;26:S65-S69.
59. Bowen DJ, Burke W, Yasui Y, McTiernan A, McLeran D. Effects of risk counseling on interest in breast cancer genetic testing for lower risk women. Genet Med 2002;4:359-365.